6-year data confirm sustained efficacy of ofatumumab

Photo of author
Written By Kampretz Bianca

Lorem ipsum dolor sit amet consectetur pulvinar ligula augue quis venenatis. 

Special report|
With friendly support from:
Novartis Pharma Vertriebs GmbH, Nuremberg

Active relapsing multiple sclerosis

In the treatment of active relapsing multiple sclerosis (EMR), monthly subcutaneous (sc) application has been shown to be effectivea, b, c Anti-CD20 antibody ofatumumabd In the two approval studies ASCLEPIOS I and II, superior efficacy compared to basic teriflunomide therapy with comparable safety and tolerability [1]. Current results from a subgroup analysis (n=465) of the ALITHIOS open-label extension study confirm for newly diagnosed casesIt istreatment-naive patients, the sustained high efficacy and favorable benefit-risk profile of ofatumumab during the observation period of up to six years [2, 3]. Even with moderate activityf RMS can be an early initiation of highly effective therapy (HETG) may be beneficial with ofatumumab [1, 3].

Source link

Leave a Comment

sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws sws mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt mdt